Eisai, Arena Pharma Announce Availability Of Belviq XR Tablets - Quick Facts

(RTTNews) - Eisai Inc. and Arena Pharmaceuticals, Inc. (ARNA) today announced the availability of Belviq XR, or lorcaserin Hcl, CIV extended-release 20 mg tablets, a new once-daily dosing option that may help some patients achieve and maintain weight loss.

According to the companies, Belviq XR is proven to be slowly absorbed in the body and last throughout the day.

The 20 mg once-daily extended-release formulation is approved for use with a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index or BMI of 30 kg/m2 or greater (obese), or BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical condition, such as high blood pressure, high cholesterol or type 2 diabetes.

Belviq CIV and Belviq XR are FDA-approved prescription weight-loss medications.

"With more than 78 million adults who are obese in this country and obesity rates on the rise, there is an increased need for additional therapeutic options to help patients better manage their weight. A once-daily, extended-release tablet provides a treatment regimen that may help patients meet their weight loss goals," Caroline Apovian, Professor of Medicine at Boston University School of Medicine said.